Clinical Data Viridian tumbles on positive data for key eye drug prospect BioPharma DiveThe data did not meet investor expectations, and could bring fierce investor debate on commercial feasibility, according to an analyst.Clinical DataOphthalmologyRead full story pharminent March 31, 2026 (Last updated: March 31, 2026) BioPharma Dive The data did not meet investor expectations, and could bring fierce investor debate on commercial feasibility, according to an analyst. Clinical DataOphthalmologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting DiseaseNext: Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy Related Stories Clinical Data Boehringer advances duo for aggressive cancers into phase 3 pharminent June 22, 2026 Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
